The retina is the layer of cells in the retina that receives light from the optic nerve and converts it into electrical signals.
It has many functions, including the ability to see and hear, and to recognize the presence of an object or object, and even the presence and absence of a person.
But it also has a role to play in the process of photocochromosis, the process by which a cat’s eye becomes damaged by the UV light.
A cat with a torn retina has no vision at all.
Scientists have discovered a way to fix that in a cat, by surgically injecting an antibody into the cat’s retinas.
The antibody is a synthetic form of a protein that was discovered by Dr. Eric Rydstrom, who is an associate professor at the Department of Biomedical Engineering at the University of Texas at Austin and is one of the leaders of the development of this technology.
“We are making a new, safe, effective drug that will be safe, nontoxic, and effective for this type of injury,” Dr. Rydstrum said in a news release.
His research has already been approved by the Food and Drug Administration, and is scheduled to be tested on humans later this year.
This technology could potentially be used to treat a wide range of eye injuries, such as cataracts and retinal detachment.
To test the new antibody, researchers at the VA Medical Center of Southwestern Pennsylvania used a cat with the type of tear that was causing the damage to their retinas, and a cat who was not injured, in an experiment.
While in the lab, the researchers injected the cat with an antibody to the protein, and monitored its effect on the cat.
They found that the antibody produced a significant reduction in the amount of damage to the retina caused by UV light in the cat compared to a control cat, and that the cat who received the antibody showed fewer retinal lesions than the cat whose retinas had been damaged by UV radiation.
The results were published online this week in the journal Current Biology.
It also led to the first studies to see if the antibody could be safely administered to cats in the clinic, using a standard protocol that involves using an eye exam, a cat scan and a blood test to confirm the cat is healthy.
Dr. Rysstrom said the antibody’s effectiveness and safety is a result of the use of a specific protein in the protein that’s produced by a small number of antibodies that bind to the proteins that make up the antibodies.
Unlike the antibodies in the drug currently used in clinical trials, the antibodies that Dr. Dominguez and Dr. Gagliano are using are specifically designed to target the proteins of the retina.
When they injected the antibody into these cats, they were able to successfully treat a large number of cats with the eye injury.
Dr. Gaggiano said the antibodies are also able to bind to retinal proteins, which allow the cat to see with its own eyesight.
“That’s something that we can’t do by using antibodies to target only one protein, or two proteins, or all proteins,” Dr Gaggiana said.
Although this study showed the antibody can help the cats, the research has not yet been tested in humans, because Dr. Hwang has not received FDA approval to administer it in humans.
Dr Hwang said she’s not interested in trying to help the cat, but is interested in finding out what makes it heal, so she and her colleagues can create a test that could be used in future treatments.
For now, she said she and Dr Rydsstrom are focused on helping the cat heal and finding a cure.
In addition to Dr. Loeser, other researchers involved in this research are Dr. Paul G. Hoch, an associate research professor at Johns Hopkins University School of Medicine, Dr. Christopher A. McPherson, an assistant professor of medicine at Columbia University Medical Center, Dr Hui-Chun Wang, an Assistant Professor of Surgery and Medical Microbiology at Johns Hawkins School of Hospital, Dr David G. Daugherty, an Associate Professor of Veterinary Surgery at University of North Carolina School of Veterinary Medicine, and Dr Robert J. Smith, a researcher at the Yale School of Forestry & Environmental Sciences.